Related Experiment Video

Updated: Jun 26, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Mechanisms of resistance to FLT3 inhibitors

S Haihua Chu1, Donald Small

  • 1Department of Oncology, Johns Hopkins University School of Medicine, CRB1-251, 1650 Orleans St., Baltimore, MD 21231-1000, USA.

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|January 24, 2009
PubMed

Insights

The study discusses resistance mechanisms to FLT3 inhibitors in acute myeloid leukemia (AML). It explores strategies to overcome resistance, focusing on combination therapies for improved long-term efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Imatinib mesylate (Gleevec) success in chronic myeloid leukemia (CML) highlights targeted cancer therapy.
  • Activating mutations in FLT3 receptor tyrosine kinase are common in acute myeloid leukemias (AMLs).
  • FLT3 inhibitors show promise but face resistance challenges.

Purpose of the Study:

  • To discuss mechanisms of resistance to FLT3 inhibitors in AML.
  • To explore strategies for overcoming resistance to FLT3 inhibitors.
  • To examine leukemogenesis and combination therapy for durable efficacy.

Main Methods:

  • Review of current literature on FLT3 inhibitor resistance.
  • Analysis of molecular mechanisms driving resistance.
  • Discussion of potential combination therapy strategies.

Main Results:

  • Primary and secondary acquired resistance can limit FLT3 inhibitor efficacy.
  • Understanding resistance mechanisms is crucial for therapeutic success.
  • Combination therapies may offer a strategy to overcome resistance.

Conclusions:

  • Resistance to FLT3 inhibitors is a significant clinical challenge in AML.
  • Further research into resistance mechanisms and combination therapies is warranted.
  • Targeted therapies combined with other agents may improve patient outcomes.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...